NCT03941587View on ClinicalTrials.gov

Comparing Intravitreal Aflibercept Monotherapy Vs Aflibercept Combined with Reduced Fluence PDT in PCV Treatment

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

June 6, 2024

Study Completion Date

June 6, 2024

Conditions
Polypoidal Choroidal Vasculopathy
Interventions
DRUG

Aflibercept + reduced fluence photodynamic therapy (RF-PDT)

Aflibercept dosage of 2mg in 0.05ml along with intravenous infusion of Verteporfin (6mg/m2)followed by laser light at a dosage of 25Joule/cm2

DRUG

Aflibercept + sham reduced fluence photodynamic therapy (RF-PDT)

Aflibercept dosage of 2mg in 0.05ml along with sham photodynamic therapy

Trial Locations (2)

168751

Singapore National Eye Centre, Singapore

Unknown

National University Hospital, Singapore

All Listed Sponsors
collaborator

National University Hospital, Singapore

OTHER

collaborator

Tan Tock Seng Hospital

OTHER

lead

Singapore National Eye Centre

OTHER_GOV

NCT03941587 - Comparing Intravitreal Aflibercept Monotherapy Vs Aflibercept Combined with Reduced Fluence PDT in PCV Treatment | Biotech Hunter | Biotech Hunter